MediWound Announces Collaboration With MIMEDX On EscharEx Phase III Study
MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a research collaboration agreement with